265 related articles for article (PubMed ID: 17408933)
1. Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.
Krishna R; Schaefer HG; Bjerrum OJ
Eur J Pharm Sci; 2007 May; 31(1):62-7. PubMed ID: 17408933
[TBL] [Abstract][Full Text] [Related]
2. Effective integration of systems biology, biomarkers, biosimulation, and modeling in streamlining drug development.
Krishna R; Schaefer HG; Bjerrum OJ
J Clin Pharmacol; 2007 Jun; 47(6):738-43. PubMed ID: 17463216
[No Abstract] [Full Text] [Related]
3. Integrating systems approaches into pharmaceutical sciences.
Westerhoff HV; Mosekilde E; Noe CR; Clemensen AM
Eur J Pharm Sci; 2008 Sep; 35(1-2):1-4. PubMed ID: 18602464
[TBL] [Abstract][Full Text] [Related]
4. Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.
Stanski DR; Rowland M; Sheiner LB
J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):199-211. PubMed ID: 16283539
[TBL] [Abstract][Full Text] [Related]
5. SysBioMed report: advancing systems biology for medical applications.
Wolkenhauer O; Fell D; De Meyts P; Blüthgen N; Herzel H; Le Novère N; Höfer T; Schürrle K; van Leeuwen I
IET Syst Biol; 2009 May; 3(3):131-6. PubMed ID: 19449974
[TBL] [Abstract][Full Text] [Related]
6. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
7. Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design.
Kansal AR; Trimmer J
Syst Biol (Stevenage); 2005 Dec; 152(4):214-20. PubMed ID: 16986263
[TBL] [Abstract][Full Text] [Related]
8. Assessing the impact of predictive biosimulation on drug discovery and development.
Michelson S
J Bioinform Comput Biol; 2003 Apr; 1(1):169-77. PubMed ID: 15290786
[TBL] [Abstract][Full Text] [Related]
9. Reducing systems biology to practice in pharmaceutical company research; selected case studies.
Benson N; Cucurull-Sanchez L; Demin O; Smirnov S; van der Graaf P
Adv Exp Med Biol; 2012; 736():607-15. PubMed ID: 22161355
[TBL] [Abstract][Full Text] [Related]
10. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
Agoram BM; Demin O
Drug Discov Today; 2011 Dec; 16(23-24):1031-6. PubMed ID: 22020181
[TBL] [Abstract][Full Text] [Related]
11. Current and future directions of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling and simulation: population approach group in Europe 19th annual meeting.
Kloft C; Poggesi I
Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1599-604. PubMed ID: 20969486
[TBL] [Abstract][Full Text] [Related]
12. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
13. The impact of systems biology and biosimulation on drug discovery and development.
Michelson S
Mol Biosyst; 2006 Jun; 2(6-7):288-91. PubMed ID: 16880946
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
15. Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences.
Mochel JP; Tyden E; Hellmann K; Vendrig JC; Şenel S; Dencker L; Cristina RT; Linden H; Schmerold I
J Vet Pharmacol Ther; 2018 Jun; 41(3):378-383. PubMed ID: 29266320
[TBL] [Abstract][Full Text] [Related]
16. Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline.
Menshykau D
Drug Discov Today; 2017 Nov; 22(11):1598-1603. PubMed ID: 28545837
[TBL] [Abstract][Full Text] [Related]
17. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
Gieschke R; Steimer JL
Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
[TBL] [Abstract][Full Text] [Related]
18. The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment.
Abi-Gerges N; McMahon C; Vargas H; Sager P; Chui R; Stevens D; Davila J; Schaub JR; Wu JC; Del Rio C; Mathes C; Miller PE; Burns-Naas LA; Ghetti A
J Pharmacol Toxicol Methods; 2019; 98():106582. PubMed ID: 31077805
[TBL] [Abstract][Full Text] [Related]
19. The impact of systems approaches on biological problems in drug discovery.
Hood L; Perlmutter RM
Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
